News | January 31, 2022
Dr Reddy’s numbers in line; launches in FY23 likely drivers: ICICI Direct
ICICI Direct analysis of Dr Reddy’s Q3FY22 results
ICICI Direct analysis of Dr Reddy’s Q3FY22 results
Acute therapies continue to report strong growth compared to chronic ones.
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
Subscribe To Our Newsletter & Stay Updated
